Martin Schwickart

1.9k total citations · 1 hit paper
22 papers, 1.4k citations indexed

About

Martin Schwickart is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Hematology. According to data from OpenAlex, Martin Schwickart has authored 22 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Hematology. Recurrent topics in Martin Schwickart's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Hemoglobinopathies and Related Disorders (4 papers) and Acute Myeloid Leukemia Research (3 papers). Martin Schwickart is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Hemoglobinopathies and Related Disorders (4 papers) and Acute Myeloid Leukemia Research (3 papers). Martin Schwickart collaborates with scholars based in United States, Germany and United Kingdom. Martin Schwickart's co-authors include Gunnar Dittmar, Matthew T. Feng, Daniel Finley, Rayappa R. Gali, Britta Müller, Suzanne Elsasser, David Leggett, Christopher N. Larsen, Vishva M. Dixit and Jinfeng Liu and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Martin Schwickart

22 papers receiving 1.4k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

2009 510 citations Martin Schwickart, Xiaodong Huang et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Schwickart United States	11	1.2k	420	365	217	169	22	1.4k
Narendra Thapa United States	22	1.1k 0.9×	603 1.4×	226 0.6×	228 1.1×	218 1.3×	32	1.7k
Frauke Schimmöller United States	17	1.2k 1.0×	980 2.3×	336 0.9×	122 0.6×	96 0.6×	35	1.9k
Robert J. Ingham Canada	21	936 0.8×	238 0.6×	409 1.1×	132 0.6×	362 2.1×	34	1.5k
Lingyan Jin China	10	1.1k 0.9×	326 0.8×	277 0.8×	138 0.6×	130 0.8×	23	1.4k
Mala Mani United States	11	1.1k 0.9×	400 1.0×	413 1.1×	137 0.6×	132 0.8×	15	1.4k
Iwona Szymkiewicz Sweden	11	1.3k 1.1×	610 1.5×	356 1.0×	126 0.6×	256 1.5×	12	1.7k
Suyong Choi United States	22	835 0.7×	512 1.2×	216 0.6×	154 0.7×	189 1.1×	29	1.3k
Julie M. Bailis United States	21	1.5k 1.2×	299 0.7×	788 2.2×	151 0.7×	194 1.1×	55	2.0k
Yong Wan United States	26	1.6k 1.3×	366 0.9×	621 1.7×	117 0.5×	365 2.2×	45	2.2k
Angela Paul United Kingdom	15	913 0.8×	222 0.5×	319 0.9×	91 0.4×	124 0.7×	18	1.3k

Countries citing papers authored by Martin Schwickart

Since Specialization

Citations

This map shows the geographic impact of Martin Schwickart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Schwickart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Schwickart more than expected).

Fields of papers citing papers by Martin Schwickart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Schwickart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Schwickart. The network helps show where Martin Schwickart may publish in the future.

Co-authorship network of co-authors of Martin Schwickart

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Schwickart. A scholar is included among the top collaborators of Martin Schwickart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Schwickart. Martin Schwickart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garbowski, Maciej, Alberto Risueño, Jeevan K. Shetty, et al.. (2023). Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion‐dependent thalassemia. American Journal of Hematology. 99(2). 182–192. 13 indexed citations

MacBeth, Kyle J., Vivek S. Chopra, Lin Tang, et al.. (2021). Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA. Experimental Hematology. 98. 47–52.e6. 8 indexed citations

Garbowski, Maciej, Alberto Risueño, Rajasekhar N.V.S. Suragani, et al.. (2021). Luspatercept Redistributes Body Iron to the Liver in Transfusion-Dependent-Thalassemia (TDT) during Erythropoietic Response. Blood. 138(Supplement 1). 761–761. 2 indexed citations

Platzbecker, Uwe, Alberto Risueño, Esther T. Chan, et al.. (2020). Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial. Blood. 136(Supplement 1). 38–39. 2 indexed citations

Acar, Melih, et al.. (2020). Rapamycin (Sirolimus) and Rap-536 Increase Red Blood Cell Parameters through Distinct Mechanisms in Wild-Type and Thalassemic Mice. Blood. 136(Supplement 1). 17–17. 2 indexed citations

Fraser, Stephanie, et al.. (2017). Current Trends in Ligand Binding Real-Time Measurement Technologies. The AAPS Journal. 19(3). 682–691. 8 indexed citations

Sheldon, Eric, Martin Schwickart, Jing Li, et al.. (2016). Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study. Advances in Therapy. 33(2). 225–251. 36 indexed citations

Song, Xuyang, Min Gyoung Pak, Carlos Chávez, et al.. (2015). Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 33(15_suppl). e14010–e14010. 2 indexed citations

Liang, Meina, Martin Schwickart, Amy Schneider, et al.. (2015). Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry Part B Clinical Cytometry. 90(2). 117–127. 36 indexed citations

10.

Song, Xuyang, Min Gyoung Pak, Carlos Chávez, et al.. (2015). Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). e14009–e14009. 8 indexed citations

11.

Vainshtein, Inna, Amy Schneider, Bo Sun, et al.. (2015). Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals. Cytometry Part B Clinical Cytometry. 90(2). 128–140. 7 indexed citations

12.

Fraser, Stephanie, et al.. (2014). Next Generation Ligand Binding Assays—Review of Emerging Real-Time Measurement Technologies. The AAPS Journal. 16(5). 914–924. 4 indexed citations

13.

Schwickart, Martin, et al.. (2014). Interference in Immunoassays to Support Therapeutic Antibody Development in Preclinical and Clinical Studies. Bioanalysis. 6(14). 1939–1951. 24 indexed citations

14.

Schwickart, Martin, Jennifer Pearson, Carlos Chávez, et al.. (2013). Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay. Journal of Immunological Methods. 403(1-2). 52–61. 9 indexed citations

15.

Dompe, Nicholas, Celina Sanchez Rivers, Li Li, et al.. (2011). A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis. Proceedings of the National Academy of Sciences. 108(43). 47 indexed citations

16.

Roskos, Lorin, Amy Schneider, Inna Vainshtein, et al.. (2011). PK–PD Modeling of Protein Drugs: Implications in Assay Development. Bioanalysis. 3(6). 659–675. 36 indexed citations

17.

Schwickart, Martin, Xiaodong Huang, Jennie R. Lill, et al.. (2009). Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 463(7277). 103–107. 510 indexed citations breakdown →

18.

Petronczki, Mark, Joao Matos, Saori Mori, et al.. (2006). Monopolar Attachment of Sister Kinetochores at Meiosis I Requires Casein Kinase 1. Cell. 126(6). 1049–1064. 146 indexed citations

19.

Schwickart, Martin, Joao Matos, Aliona Bogdanova, et al.. (2005). The Yeast APC/C Subunit Mnd2 Prevents Premature Sister Chromatid Separation Triggered by the Meiosis-Specific APC/C-Ama1. Cell. 120(6). 773–788. 80 indexed citations

20.

Elsasser, Suzanne, Rayappa R. Gali, Martin Schwickart, et al.. (2002). Proteasome subunit Rpn1 binds ubiquitin-like protein domains. Nature Cell Biology. 4(9). 725–730. 370 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact